Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 15/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 15/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 15/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 15/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 15/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 15/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 15/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 15/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 15/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 2/20 | 0.41 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17078440 | 0.84 | HDAC3 (0.70) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17078407 | 0.76 | HDAC3 (0.80) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17087431 | 0.76 | HDAC3 (0.80) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17087430 | 0.73 | HDAC3 (0.78) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17078391 | 0.73 | CDK5 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17087521 | 0.73 | CDK1 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL18490839 | 0.73 | HDAC3 (0.65) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL17078409 | 0.73 | HDAC3 (0.65) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4581162 | 0.71 | HDAC6 (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL22587405 | 0.70 | CDK1 (0.58) | CDK5CDK5R1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180265512-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-09-20 | — | — | US | disclosed |
| US-9957270-B2 | Fused pyrimidine-based hydroxamate derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-01 | — | — | US | disclosed |
| US-20170044162-A1 | Fused Pyrimidine-Based Hydroxamate Derivatives | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-02-16 | — | — | US | disclosed |
| EP-3116876-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | Agency For Science, Technology And Research (SG) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015137887-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044162-A1 | Fused Pyrimidine-Based Hydroxamate Derivatives | HDAC1, HDAC2, HDAC5 | HDAC3 4/4885HDAC4 8/4885HDAC1 1/4885 |
| US-20180265512-A1 | FUSED PYRIMIDINE-BASED HYDROXAMATE DERIVATIVES | HDAC1, HDAC5, HDAC2 | HDAC3 4/4885HDAC4 8/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.